1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treatment effect, but there may be strong justification for borrowing information from a larger patient group within the same trial, while allowing for differences between populations. Our aim was to develop methods for eliciting expert opinions about differences in treatment effect between patient populations, and to incorporate these opinions into a Bayesian analysis.

          Methods

          We used an interaction parameter to model the relationship between underlying treatment effects in two subgroups. Elicitation was used to obtain clinical opinions on the likely values of the interaction parameter, since this parameter is poorly informed by the data. Feedback was provided to experts to communicate how uncertainty about the interaction parameter corresponds with relative weights allocated to subgroups in the Bayesian analysis. The impact on the planned analysis was then determined.

          Results

          The methods were applied to an ongoing non-inferiority trial designed to compare antiretroviral therapy regimens in 707 children living with HIV and weighing ≥ 14 kg, with an additional group of 85 younger children weighing < 14 kg in whom the treatment effect will be estimated separately. Expert clinical opinion was elicited and demonstrated that substantial borrowing is supported. Clinical experts chose on average to allocate a relative weight of 78% (reduced from 90% based on sample size) to data from children weighing ≥ 14 kg in a Bayesian analysis of the children weighing < 14 kg. The total effective sample size in the Bayesian analysis was 386 children, providing 84% predictive power to exclude a difference of more than 10% between arms, whereas the 85 younger children weighing < 14 kg provided only 20% power in a standalone frequentist analysis.

          Conclusions

          Borrowing information from a larger subgroup or subgroups can facilitate estimation of treatment effects in small subgroups within a clinical trial, leading to improved power and precision. Informative prior distributions for interaction parameters are required to inform the degree of borrowing and can be informed by expert opinion. We demonstrated accessible methods for obtaining opinions.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12874-022-01539-3.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Book: not found

          Uncertain Judgements: Eliciting Experts' Probabilities

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Robust meta-analytic-predictive priors in clinical trials with historical control information.

            Historical information is always relevant for clinical trial design. Additionally, if incorporated in the analysis of a new trial, historical data allow to reduce the number of subjects. This decreases costs and trial duration, facilitates recruitment, and may be more ethical. Yet, under prior-data conflict, a too optimistic use of historical data may be inappropriate. We address this challenge by deriving a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data. This prospective approach is equivalent to a meta-analytic-combined analysis of historical and new data if parameters are exchangeable across trials. The prospective Bayesian version requires a good approximation of the meta-analytic-predictive prior, which is not available analytically. We propose two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations. Moreover, since one of the mixture components is usually vague, mixture priors will often be heavy-tailed and therefore robust. Further robustness and a more rapid reaction to prior-data conflicts can be achieved by adding an extra weakly-informative mixture component. Use of historical prior information is particularly attractive for adaptive trials, as the randomization ratio can then be changed in case of prior-data conflict. Both frequentist operating characteristics and posterior summaries for various data scenarios show that these designs have desirable properties. We illustrate the methodology for a phase II proof-of-concept trial with historical controls from four studies. Robust meta-analytic-predictive priors alleviate prior-data conflicts ' they should encourage better and more frequent use of historical data in clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.

              In recent years, cancers once viewed as relatively homogeneous in terms of organ location and treatment strategy are now better understood to be increasingly heterogeneous across biomarker and genetically defined patient subgroups. This has produced a shift toward development of biomarker-targeted agents during a time when funding for cancer research has been limited; as a result, the need for improved operational efficiency in studying many agent-and-target combinations in parallel has emerged. Platform trials, basket trials, and umbrella trials are new approaches to clinical research driven by this need for enhanced efficiency in the modern era of increasingly specific cancer subpopulations and decreased resources to study treatments for individual cancer subtypes in a traditional way. In this review, we provide an overview of these new types of clinical trial designs, including discussions of motivation for their use, recommended terminology, examples, and challenges encountered in their application.
                Bookmark

                Author and article information

                Contributors
                becky.turner@ucl.ac.uk
                Journal
                BMC Med Res Methodol
                BMC Med Res Methodol
                BMC Medical Research Methodology
                BioMed Central (London )
                1471-2288
                20 February 2022
                20 February 2022
                2022
                : 22
                : 49
                Affiliations
                [1 ]GRID grid.415052.7, ISNI 0000 0004 0606 323X, Medical Research Council Clinical Trials Unit at University College London, ; 90 High Holborn, London, WC1V 6LJ UK
                [2 ]GRID grid.424537.3, ISNI 0000 0004 5902 9895, Department of Paediatric Infectious Diseases, , Great Ormond Street Hospital for Children NHS Foundation Trust, ; London, UK
                [3 ]GRID grid.83440.3b, ISNI 0000000121901201, UCL Great Ormond Street Institute of Child Health, ; London, UK
                [4 ]GRID grid.415293.8, ISNI 0000 0004 0383 9602, King Edward VIII Hospital, ; Durban, South Africa
                [5 ]GRID grid.16463.36, ISNI 0000 0001 0723 4123, Department of Paediatrics and Child Health, , University of KwaZulu Natal, ; Durban, South Africa
                [6 ]GRID grid.421981.7, Makerere University- Johns Hopkins University Research Collaboration, ; Kampala, Uganda
                [7 ]GRID grid.417371.7, ISNI 0000 0004 0635 423X, Family Center for Research With Ubuntu, Department of Paediatrics and Child Health, , Tygerberg Hospital and Stellenbosch University, ; Cape Town, South Africa
                [8 ]GRID grid.7132.7, ISNI 0000 0000 9039 7662, PHPT/IRD UMI174, Faculty of Associated Medical Sciences, , Chiang Mai University, ; Chiang Mai, Thailand
                [9 ]GRID grid.10025.36, ISNI 0000 0004 1936 8470, Department of Molecular & Clinical Pharmacology, , University of Liverpool, ; Liverpool, UK
                [10 ]GRID grid.436163.5, ISNI 0000 0004 0648 1108, Joint Clinical Research Centre, ; Kampala, Uganda
                [11 ]GRID grid.436163.5, ISNI 0000 0004 0648 1108, Joint Clinical Research Centre, ; Mbarara, Uganda
                [12 ]GRID grid.417895.6, ISNI 0000 0001 0693 2181, Department of Paediatric Infectious Diseases, , Imperial College Healthcare NHS Trust, ; London, UK
                [13 ]GRID grid.13001.33, ISNI 0000 0004 0572 0760, University of Zimbabwe Clinical Research Centre, ; Harare, Zimbabwe
                [14 ]GRID grid.79746.3b, ISNI 0000 0004 0588 4220, University Teaching Hospital, ; Lusaka, Zambia
                [15 ]GRID grid.11194.3c, ISNI 0000 0004 0620 0548, Department of Paediatrics and Child Health, School of Medicine, , College of Health Sciences, Makerere University, ; Kampala, Uganda
                [16 ]Hospital, 12 de Octubre, Madrid, Spain
                [17 ]GRID grid.7445.2, ISNI 0000 0001 2113 8111, Imperial College, ; London, UK
                [18 ]GRID grid.412563.7, ISNI 0000 0004 0376 6589, Department of Paediatrics, , Birmingham Chest Clinic and Heartlands Hospital, University Hospitals Birmingham, ; Birmingham, UK
                Article
                1539
                10.1186/s12874-022-01539-3
                8858505
                35184739
                ed2b1fc9-710f-4d13-8cf2-002001ce3364
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 29 April 2021
                : 9 February 2022
                Funding
                Funded by: UK Medical Research Council
                Award ID: MC_UU_12023/26
                Award ID: MC_UU_12023/21
                Funded by: ViiV Healthcare
                Funded by: Paediatric European Network for Treatment of AIDS (PENTA) Foundation
                Funded by: INSERM-ANRS
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2022

                Medicine
                paediatric trials,subgroups,small samples,bayesian analysis,borrowing information
                Medicine
                paediatric trials, subgroups, small samples, bayesian analysis, borrowing information

                Comments

                Comment on this article